Cobimetinib - Genentech/Exelixis
Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518Latest Information Update: 08 Jul 2024
At a glance
- Originator Exelixis
- Developer Bristol-Myers Squibb; Exelixis; Genentech; InxMed; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
- Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Malignant melanoma
- Registered Histiocytosis
- Phase III Colorectal cancer
- Phase II Brain metastases; Breast cancer; Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Triple negative breast cancer; Urogenital cancer; Vascular disorders
- Phase I/II Multiple myeloma; Pancreatic cancer; Solid tumours
- Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Uveal melanoma
- No development reported Acute myeloid leukaemia
Most Recent Events
- 31 May 2024 Pharmacodynamics, efficacy and adverse events data from a phase II TRICOTEL trial in Brain metastases presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 05 Apr 2024 Interim adverse events and efficacy data from the phase-Ib/II MORPHEUS-PDAC trial in Pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 09 Dec 2023 Adverse events and efficacy data from a phase II trial in Histiocytosis were presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)